Molecure

First patient in the UK is dosed in the OATD-01 phase 2 KITE study in pulmonary sarcoidosis

OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis In the phase 2 clinical trial (KITE study), patients will take a daily oral dose of 25mg OATD-01 or placebo (in tablet form) for 12 weeks The double-blind, randomised, placebo-controlled study...
Żwirki i Wigury 101, 02-089 Warsaw

+48(22)5526724